Navigation Links
First evidence for DNA-based vaccination against chronic hepatitis C
Date:4/23/2009

Copenhagen, Denmark, Thursday 23 April: The first-proof-of-concept for a DNA-based therapeutic vaccination against chronic hepatitis C was announced today at EASL 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark.

In the first clinical trial of a therapeutic vaccination using naked DNA delivered by in vivo electroporation (EP), antiviral effects were shown in patients with hepatitis C (HCV). Researchers hope that this will encourage further clinical development. The data also provide further evidence for the antiviral role of the HCV-specific T cell response.

It is estimated that some 3% of the world's population is infected with HCV. In industrialised countries, hepatitis C accounts for 70% of chronic hepatitis cases. One of the main concerns is that HCV infection remains asymptomatic until advanced stages of the disease.

Clearance of HCV infection correlates with activation of the host T cell response. Therefore, in this study, researchers developed a T cell vaccine based on a codon-optimised HCV non-structural (NS) 3/4A DNA-gene expressed under the control of the cytomegalovirus immediate-early promoter (ChronVac-C) delivered by in vivo electroporation (EP). A first phase I/IIa clinical trial in HCV infected patients is currently ongoing.

Professor Matti Sallberg of Laboratory Medicine, the Karolinska Institutet, Stockholm, Sweden, who led the study, said: "In 50-80% of adult cases, the immune system fails to eliminate the HCV virus and the disease becomes chronic. Given that only about 50% of HCV infected persons are diagnosed in most developed countries and that two-thirds need to undergo antiviral treatment, this new vaccination has huge implications in terms of the future management of this widespread disease."

In this study, a volume of 0.5 ml saline containing ChronVac-C DNA was injected at 1 cm depth in the deltoid muscle. This was followed by two 60ms electrical pulses administered using a 1.5 cm four-electrode array (Medpulser DDS; Inovio, CA, US). The study aims were safety, immunogenicity, and effects on the viral load. Twelve treatment naive patients infected with HCV genotype 1 and a viral load <800,000 IU/ml were divided in four groups of 167 g, 500 g, and 1,500 g given as four monthly doses of DNA.

In the 167g group, no severe side effects were observed, two patients mounted transient T cell responses, and none had a reduced viral load. In the 500g dose, no severe side effects were observed, and two developed better sustained HCV-specific T cell responses. Simultaneous with these responses, both patients had reductions in the viral load of up to 0.89 log10 and 1.5 log10, respectively. In the third patient, no immune response developed and no clear reductions in the viral load were seen. In the 1,500g dose, no severe side effects were observed, and one patient developed HCV-specific T cell response. Two patients had reductions in the viral load of up to 1.2 log10 and 2.4 log10, respectively. Thus, 67% (four out of six) of patients in the two highest dose groups had reductions in the viral load exceeding 0.5 log10 lasting for two to >10 weeks. Of these, three had activations of the HCV-specific T cell responses at the time of the reductions in the viral load.


'/>"/>

Contact: Camilla Dormer
easlpressoffice@cohnwolfe.com
44-787-619-0439
European Association for the Study of the Liver
Source:Eurekalert

Related medicine news :

1. BlueSky Medical Staffing Software Launches First Job Aggregation Engine App and Releases API for Developers
2. Sarasota Veterinary Neurologist Offers Free pet First aid Guide
3. NuVasive Reports First Quarter 2009 Financial Results
4. Torchmark Corporation Reports First Quarter 2009 Results
5. AMICAS Schedules First Quarter 2009 Earnings Results Conference Call
6. West to Host 2009 First Quarter Conference Call
7. VirtualScopics Schedules First Quarter 2009 Earnings Announcement
8. Video: U.S. Announcement - First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure
9. Agito Networks Named to the First Annual InformationWeek Startup 50 Listing
10. Medifast, Inc. to Announce First Quarter Fiscal Year 2009 Financial Results on Wednesday, April 29, 2009
11. Kensey Nash Reports Third Quarter and First Nine Month Fiscal Year 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... AvePoint ... seventh North American office location in Richmond, Virginia, located at the Riverfront Plaza, 901 ... attended by Lieutenant Governor of Virginia Ralph S. Northam and Mayor of Richmond Levar ...
(Date:3/28/2017)... ... March 28, 2017 , ... A recent Bellwether ... teacher quality, the field must first improve teacher preparation program design. It then ... next” and that decades of input- and outcome-based research has failed to improve ...
(Date:3/28/2017)... ... March 28, 2017 , ... For many women, getting birth control isn’t as easy as it ... either don’t have access to a health care facility or a pharmacy within 60 minutes ... the United States or for many who are faced with health or personal issues that ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Ruel Williamson brings his extensive knowledge of appraisals, property values, ad valorem taxation, ... real estate valuation industry for more than 40 years. , “Ruel is a ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... state legislatures and Congress to protect parental rights and civil liberties, and to ... in America. , The demonstration coincides with a press conference taking place Friday ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... -- According to a new market research report "Medical Radiation ... Survey Meter, Solid-State), Products (Personal Dosimeters, OSL, Badges), Safety (Apron, Shields, Face ... market is expected to reach USD 1,215.4 Million by 2021 from USD ... 2021. Continue Reading ... ...
(Date:3/29/2017)... 2017 Research and Markets has announced the ... to their offering. ... The global lifestyle drugs market to grow at a CAGR ... Global Lifestyle Drugs Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:3/29/2017)... Mar 29, 2017 Research and Markets has ... Forecast to 2023" report to their offering. ... The ablation device global market ... $20,995.5 million by 2023. Ablation is the minimally ... purposes, from cancerous or diseased tissue removal, to the removal of ...
Breaking Medicine Technology: